X4 Pharmaceuticals (XFOR) Revenue (2018 - 2026)
X4 Pharmaceuticals' (XFOR) quarterly Revenue came in at $2.6 million in Q4 2025, up 79.08% YoY from $1.4 million in Q4 2024, and up 45.5% on a QoQ basis from $1.8 million in Q3 2025.
X4 Pharmaceuticals (XFOR) Revenue (2018 - 2026) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 4 years of Revenue data on file, last reported at $2.6 million in Q4 2025.
- Quarterly Revenue rose 79.08% year-over-year to $2.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35.1 million (up 1273.21% YoY) and the FY2025 annual result came in at $35.1 million, up 1273.21% from the prior year.
- Revenue grew to $2.6 million in Q4 2025, from $1.8 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $28.8 million in Q1 2025 to a low of $560000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn | 8.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.81 Mn |
| Dec 31, 2025 | 2.57 Mn |
| Sep 30, 2025 | 1.77 Mn |
| Jun 30, 2025 | 1.97 Mn |
| Mar 31, 2025 | 28.81 Mn |
| Dec 31, 2024 | 1.43 Mn |
| Sep 30, 2024 | 560,000.00 |
| Jun 30, 2024 | 563,000.00 |
| Mar 31, 2020 | 3.00 Mn |
| Dec 31, 2018 | 3.50 Mn |